Sensus Healthcare (NASDAQ:SRTS) Price Target Cut to $8.00 by Analysts at HC Wainwright

Key Points

• HC Wainwright has decreased its price target for Sensus Healthcare from $12.00 to $8.00, maintaining a "buy" rating, suggesting a potential upside of 151.57% from the last close.
• Sensus Healthcare's stock saw an 8.1% decline on Tuesday, trading at $3.18, well below its 52-week high of $9.33.
• The company reported a loss of ($0.06) earnings per share for its latest quarterly earnings, missing analyst expectations and generating revenues of $7.32 million, lower than the anticipated $9.30 million.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) had its price target decreased by equities research analysts at HC Wainwright from $12.00 to $8.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's target price would suggest a potential upside of 138.81% from the stock's current price. HC Wainwright also issued estimates for Sensus Healthcare's Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.43) EPS, Q1 2026 earnings at ($0.04) EPS, Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at $0.09 EPS and FY2026 earnings at $0.01 EPS.

Other equities research analysts also recently issued reports about the stock. Lake Street Capital dropped their price objective on shares of Sensus Healthcare from $13.00 to $6.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Maxim Group dropped their price objective on shares of Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Finally, Wall Street Zen downgraded shares of Sensus Healthcare from a "hold" rating to a "sell" rating in a report on Sunday, June 22nd.

Sensus Healthcare Trading Down 2.6%

Shares of NASDAQ:SRTS traded down $0.09 during midday trading on Tuesday, reaching $3.35. The company had a trading volume of 72,653 shares, compared to its average volume of 244,890. The company's 50 day moving average price is $4.69 and its 200 day moving average price is $4.89. The stock has a market cap of $55.07 million, a P/E ratio of -55.83 and a beta of 1.34. Sensus Healthcare has a 52-week low of $3.03 and a 52-week high of $9.33.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by ($0.07). The firm had revenue of $7.32 million during the quarter, compared to the consensus estimate of $9.30 million. Sensus Healthcare had a negative net margin of 2.26% and a negative return on equity of 1.58%. Research analysts forecast that Sensus Healthcare will post 0.32 EPS for the current fiscal year.

Institutional Investors Weigh In On Sensus Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Sensus Healthcare during the first quarter valued at about $71,000. Millennium Management LLC increased its position in shares of Sensus Healthcare by 256.6% in the fourth quarter. Millennium Management LLC now owns 85,329 shares of the company's stock worth $590,000 after purchasing an additional 61,403 shares during the last quarter. IFP Advisors Inc increased its position in shares of Sensus Healthcare by 37.2% in the first quarter. IFP Advisors Inc now owns 18,800 shares of the company's stock worth $89,000 after purchasing an additional 5,100 shares during the last quarter. Pacific Ridge Capital Partners LLC bought a new position in shares of Sensus Healthcare in the first quarter worth approximately $542,000. Finally, Bank of New York Mellon Corp increased its position in shares of Sensus Healthcare by 3.9% in the first quarter. Bank of New York Mellon Corp now owns 141,971 shares of the company's stock worth $672,000 after purchasing an additional 5,289 shares during the last quarter. 25.30% of the stock is currently owned by institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.